Literature DB >> 18586330

Serum BAFF expression in patients with myasthenia gravis.

Jee Young Kim1, Young Yang, Joon-Shik Moon, Eun Young Lee, Sun Hwha So, Hong-Soo Lee, Kee Duk Park, Young-Chul Choi.   

Abstract

A B-cell activating factor of the tumor necrosis factor (TNF) family (BAFF) is an essential B-cell survival factor. Myasthenia gravis (MG) is one of the most typical antibody-mediated autoimmune disorders. To test whether serum BAFF levels are increased in MG patients, we compared the serum BAFF levels of 40 MG patients with those of 30 healthy controls. Serum BAFF levels of MG group were significantly higher than those of healthy group. These results suggested that the BAFF might play a role in the immunopathogenesis of MG and further study on B-cell and T-cell activation may be needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18586330     DOI: 10.1016/j.jneuroim.2008.05.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  21 in total

1.  Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model.

Authors:  Muriel Sudres; Marie Maurer; Marieke Robinet; Jacky Bismuth; Frédérique Truffault; Diane Girard; Nadine Dragin; Mohamed Attia; Elie Fadel; Nicola Santelmo; Camille Sicsic; Talma Brenner; Sonia Berrih-Aknin
Journal:  JCI Insight       Date:  2017-04-06

2.  BAFF serum levels in myasthenia gravis: effects of therapy.

Authors:  Flavia Scuderi; Paolo E Alboini; Emanuela Bartoccioni; Amelia Evoli
Journal:  J Neurol       Date:  2011-05-11       Impact factor: 4.849

3.  Correlations of TNF-α gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis in a northern Chinese Han population.

Authors:  H-W Yang; P Lei; Y-C Xie; Z-L Han; D Li; S-H Wang; Z-L Sun
Journal:  Cancer Gene Ther       Date:  2017-04-21       Impact factor: 5.987

4.  Deleted in Breast Cancer 1 Suppresses B Cell Activation through RelB and Is Regulated by IKKα Phosphorylation.

Authors:  Sinyi Kong; Hongxin Dong; Jianxun Song; Muthusamy Thiruppathi; Bellur S Prabhakar; Quan Qiu; Zhenghong Lin; Eduardo Chini; Bin Zhang; Deyu Fang
Journal:  J Immunol       Date:  2015-09-16       Impact factor: 5.422

5.  B Cell-Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease.

Authors:  Francesca Polverino; Borja G Cosio; Jaime Pons; Maria Laucho-Contreras; Paula Tejera; Amanda Iglesias; Angel Rios; Andreas Jahn; Jaume Sauleda; Miguel Divo; Victor Pinto-Plata; Lynette Sholl; Ivan O Rosas; Alvar Agustí; Bartolome R Celli; Caroline A Owen
Journal:  Am J Respir Crit Care Med       Date:  2015-09-15       Impact factor: 21.405

6.  Silencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravis.

Authors:  JunMei Zhang; Ge Jia; Qun Liu; Jue Hu; Mei Yan; BaiFeng Yang; Huan Yang; WenBin Zhou; Jing Li
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

Review 7.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

8.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

9.  B-cell-activating factor and autoimmune myasthenia gravis.

Authors:  Samia Ragheb; Robert P Lisak
Journal:  Autoimmune Dis       Date:  2011-11-28

10.  Serum proteomic, peptidomic and metabolomic profiles in myasthenia gravis patients during treatment with Qiangji Jianli Fang.

Authors:  Chunmei Wang; Yonghai Lu; Zhixi Chen; Xiaobin Liu; Huangquan Lin; Hui Zhao; Jinyan Chen; Yiuwa Kwan; Saiming Ngai
Journal:  Chin Med       Date:  2012-07-28       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.